Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Xiamen Amoytop Biotech Co's Enterprise Value is ¥23,849 Mil.
Xiamen Amoytop Biotech Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ¥1,147 Mil. Therefore, Xiamen Amoytop Biotech Co's EV-to-EBIT ratio for today is 20.79.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Xiamen Amoytop Biotech Co (SHSE:688278) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Xiamen Amoytop Biotech Co's EV-to-EBIT for today is
Xiamen Amoytop Biotech Co's current Enterprise Value is ¥23,849 Mil.
Xiamen Amoytop Biotech Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,147 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Xiamen Amoytop Biotech Co's EV-to-EBITDA for today is:
Xiamen Amoytop Biotech Co's current Enterprise Value is ¥23,849 Mil.
Xiamen Amoytop Biotech Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,147 Mil.
Xiamen Amoytop Biotech Co's current Enterprise Value is ¥23,849 Mil.
Xiamen Amoytop Biotech Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥3,820 Mil.
Xiamen Amoytop Biotech Co's current Enterprise Value is ¥23,849 Mil.
Xiamen Amoytop Biotech Co's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥657 Mil.
Xiamen Amoytop Biotech Co's current Enterprise Value is ¥23,849 Mil.
Xiamen Amoytop Biotech Co's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥386 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xiamen Amoytop Biotech Co Enterprise Value Related Terms
Xiamen Amoytop Biotech Co Enterprise Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688278 vs VRTX, REGN, RVMD: Enterprise Value Comparison
For the Biotechnology subindustry, Xiamen Amoytop Biotech Co's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xiamen Amoytop Biotech Co Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xiamen Amoytop Biotech Co's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Xiamen Amoytop Biotech Co's Enterprise Value falls into.
Xiamen Amoytop Biotech Co Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Xiamen Amoytop Biotech Co's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xiamen Amoytop Biotech Co (SHSE:688278) has a Enterprise Value of ¥23,849 Mil as of Jul. 27, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Xiamen Amoytop Biotech Co and its competitors.
Is Xiamen Amoytop Biotech Co's Enterprise Value too high?
Xiamen Amoytop Biotech Co's current Enterprise Value is ¥23,849 Mil. Overall, Xiamen Amoytop Biotech Co has a GF Score™ of 75/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Xiamen Amoytop Biotech Co's Enterprise Value compare to VRTX and REGN?
Xiamen Amoytop Biotech Co's Enterprise Value of ¥23,849 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Xiamen Amoytop Biotech Co and its competitors. Xiamen Amoytop Biotech Co's current Enterprise Value is ¥23,849 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xiamen Amoytop Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Xiamen Amoytop Biotech Co (SHSE:688278) is currently considered Possible Value Trap. The stock's GF Value™ is ¥106.91, compared to a current price of ¥60.63 — trading 43.3% below its estimated fair value. The current Enterprise Value is ¥23,849 Mil. Xiamen Amoytop Biotech Co's overall GF Score™ is 75/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Xiamen Amoytop Biotech Co (SHSE:688278), the current Enterprise Value is ¥23,849 Mil as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xiamen Amoytop Biotech Co (SHSE:688278) Overvalued in 2026?
Based on GuruFocus' analysis, Xiamen Amoytop Biotech Co stock appears to be undervalued.
The current stock price of ¥60.63 is trading 43.3% below its estimated GF Value™ of ¥106.91.
GuruFocus considers Xiamen Amoytop Biotech Co to be Possible Value Trap.
Key valuation signals for SHSE:688278:
Enterprise Value: ¥23,849 Mil
GF Value™: ¥106.91 vs. price of ¥60.63 (43.3% below fair value)
No single metric tells the full story. See the SHSE:688278 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xiamen Amoytop Biotech Co Ltd operates as a drug development company. The Company develops and sells protein drugs, interferon drugs, and other products.
75GF Score
Get the complete analysis for SHSE:688278
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688278 has been successfully added to your 
